The future of psychopharmacology of depression.
The DOI matches its Crossref record.
Abstract
Article AbstractThere are clear limitations to the currently approved pharmacotherapies of depression, including the fact that they are all essentially monoamine-based, have modest efficacy and a relatively slow onset of efficacy, and suffer from significant tolerability issues, particularly in the long term, including sexual dysfunction, weight gain, and cognitive impairments. This article reviews some of the most promising novel mechanisms that are not represented in compounds currently approved for depression in either the United States or Europe and that may represent the future of the psychopharmacologic treatment of depression, potentially addressing some of the efficacy and tolerability issues of antidepressants on the market. These potential antidepressant treatments include the multimodal serotonergic agents, the triple uptake inhibitors, the neurokinin-based novel therapies, the glutamatergic treatments, the nicotinic receptor-based treatments, the neurogenesis-based treatments, and antiglucocorticoid therapies. Some of these mechanisms appear to be more advanced in terms of drug development than others, but they all contribute to the global effort to develop more effective and better tolerated treatments for major depressive disorder.J Clin Psychiatry 2010;71(8):971-975Submitted: May 5, 2010; accepted June 17, 2010 (doi:10.4088/JCP.10m06223blu). Corresponding author: Maurizio Fava, MD, Depression Clinical and Research Program, Massachusetts General Hospital, 55 Fruit St, Bulfinch 351, Boston, MA 02114 (MFava@Partners.org).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cited by
Dopamine system dysregulation in major depressive disorders
Belujon, P., & Grace, A. A. (2017) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyx056 · Cited by 754
“This new generation of antidepressant is suggested to have comparable antidepressant efficacy to other drug classes, but is more tolerable (for review Chang and Fava, 2010).”
BackgroundBang-Andersen, B., Ruhland, T., Jørgensen, M., Smith, G., Frederiksen, K., Jensen, K. G., Zhong, H., Nielsen, S. M., Hogg, S., Mørk, A., et al. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm101459g · Cited by 606
Single-Dose Psilocybin Treatment for Major Depressive Disorder: A Randomized Clinical Trial
Raison, C. L., Sanacora, G., Woolley, J., Heinzerling, K., Dunlop, B. W., Brown, R. T., Kakar, R., Hassman, M., Trivedi, R. P., Robison, R., et al. (2023) · JAMA · doi:10.1001/jama.2023.14530 · Cited by 545
Baldessarini, R. J. (2013) · doi:10.1007/978-1-4614-3710-9 · Cited by 365
Rediscovering Trazodone for the Treatment of Major Depressive Disorder
Fagiolini, A., Comandini, A., Dell’Osso, M. C., & Kasper, S. (2012) · CNS Drugs · doi:10.1007/s40263-012-0010-5 · Cited by 228
“SSRIs and their derivative compounds, the serotonin-noradrenaline (norepinephrine) reuptake inhibitors (SNRIs) and noradrenaline reuptake inhibitors (NERIs), have since been shown to be comparable in efficacy and more tolerable than older agents such as tricyclic antidepressants (TCAs) and monoamine oxidase inhibitors…”
BackgroundHaenisch, B., & Bönisch, H. (2011) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2010.12.002 · Cited by 210
“…has limited the development of DATinhibiting ADs but “triple uptake inhibitors” which inhibit SERT, NAT and DAT are currently underway since they are expected to enhance overall efficacy, address anhedonia, apathy and cognitive impairment and minimize fatique and sleepiness (Chang & Fava, 2010).”
Song, Y., Sun, R., Ji, Z., Li, X., Fu, Q., & Ma, S. (2018) · Life Sciences · doi:10.1016/j.lfs.2018.05.038 · Cited by 92
Fatigue as a residual symptom of depression.
Targum, S. D., & Fava, M. (2011) · PubMed Central · Cited by 115
Schmauss, C. (2015) · Scientific Reports · doi:10.1038/srep08171 · Cited by 70
Chen, W., Li, Y., Xue, R., Li, Y., Su, R., Zhang, Y., & Li, J. (2011) · NeuroToxicology · doi:10.1016/j.neuro.2011.03.008 · Cited by 69
Abolfazli, R., Hosseini, M., Ghanizadeh, A., Ghaleiha, A., Tabrizi, M., Raznahan, M., Golalizadeh, M., & Akhondzadeh, S. (2011) · Depression and Anxiety · doi:10.1002/da.20801 · Cited by 60
“Although options for pharmacologic treatment have expanded significantly in the past 20 years, between one- and two-thirds of patients will not respond to the first antidepressant prescribed, and 15–33% will not respond to multiple interventions.[22] Patients suffering from treatment-resistant depression (TRD) experie…”
BackgroundIntravenous Ketamine for Treatment-Resistant Major Depressive Disorder
Covvey, J. R., Crawford, A. N., & Lowe, D. K. (2012) · Annals of Pharmacotherapy · doi:10.1345/aph.1q371 · Cited by 58
Schwarz, E., Doan, N. T., Pergola, G., Westlye, L. T., Kaufmann, T., Wolfers, T., Brecheisen, R., Quarto, T., Ing, A. J., Di Carlo, P., et al. (2019) · Translational Psychiatry · doi:10.1038/s41398-018-0225-4 · Cited by 49
Multi-modality: a new approach for the treatment of major depressive disorder
Richelson, E. (2013) · International Journal of Neuropsychopharmacology · doi:10.1017/s1461145712001605 · Cited by 49
“Recently, the term ‘multimodal’ was coined for compounds that contain at least two separate pharmacological modes of action that complement each other in terms of efficacy or tolerability (Nutt, 2009 ; Chang and Fava, 2010).”
BackgroundZhang, Y., Zheng, G., Fu, T., Hong, J., Li, F., Yao, X., Xue, W., & Zhu, F. (2020) · Physical Chemistry Chemical Physics · doi:10.1039/c9cp05764a · Cited by 48
Fava, M., Johe, K., Ereshefsky, L., Gertsik, L. G., English, B. A., Bilello, J. A., Thurmond, L. M., Johnstone, J., Dickerson, B. C., Makris, N., et al. (2016) · Molecular Psychiatry · doi:10.1038/mp.2015.178 · Cited by 45
Harro, J., Kanarik, M., Matrov, D., & Panksepp, J. (2011) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2011.02.016 · Cited by 47
Vilazodone: In Major Depressive Disorder
Frampton, J. E. (2011) · CNS Drugs · doi:10.2165/11207550-000000000-00000 · Cited by 49
Vilazodone: A Review in Major Depressive Disorder in Adults
McCormack, P. L. (2015) · Drugs · doi:10.1007/s40265-015-0490-y · Cited by 39
“These strategies have led to the development of multimodal serotonergic agents [7].”
BackgroundBenarous, X., Raffin, M., Bodeau, N., Dhossche, D. M., Cohen, D., & Consoli, A. (2016) · Child Psychiatry & Human Development · doi:10.1007/s10578-016-0637-4 · Cited by 46
Early interventions for youths at high risk for bipolar disorder: a developmental approach
Benarous, X., Consoli, A., Milhiet, V., & Cohen, D. (2016) · European Child & Adolescent Psychiatry · doi:10.1007/s00787-015-0773-6 · Cited by 35
Akbari, V., Ghobadi, S., Mohammadi, S., & Khodarahmi, R. (2019) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2019.108218 · Cited by 33
Smith, L. M., Paz, M. S., LaGasse, L. L., Derauf, C., Newman, E., Shah, R., Arria, A. M., Huestis, M. A., Haning, W., Strauss, A. A., et al. (2012) · Depression and Anxiety · doi:10.1002/da.21956 · Cited by 35
Magnesium Isoglycyrrhizinate attenuates lipopolysaccharide-induced depressive-like behavior in mice
Jiang, W., Chen, Q., Li, P., Lu, Q., Pei, X., Sun, Y., Wang, G., & Hao, K. (2016) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2016.12.033 · Cited by 28
Papakostas, G. I., Johe, K. K., Hand, H., Drouillard, A., Russo, P. A., Kay, G. G., Kashambwa, R., Hoeppner, B. B., Flynn, M., Yeung, A., et al. (2019) · Molecular Psychiatry · doi:10.1038/s41380-018-0334-8 · Cited by 27
Wang, M., Chen, Q., Li, M., Zhou, W., Ma, T., Wang, Y., & Gu, S. (2014) · Peptides · doi:10.1016/j.peptides.2014.04.009 · Cited by 26
Longer-term open-label study of adjunctive riluzole in treatment-resistant depression
Sakurai, H., Dording, C., Yeung, A., Foster, S., Jain, F., Chang, T., Trinh, N.-H., Bernard, R., Boyden, S., Iqbal, S. Z., et al. (2019) · Journal of Affective Disorders · doi:10.1016/j.jad.2019.06.065 · Cited by 20
“, 2017), the limited efficacy of current drug treatments for depression represents an extraordinary need for discovering and applying novel antidepressant mechanisms beyond the monoamines (Papakostas and Ionescu, 2015; Newport et al., 2015; Chang and Fava, 2010).”
BackgroundSelf-citationBuoli, M., Rovera, C., Pozzoli, S. M., Fiorentini, A., Cremaschi, L., Caldiroli, A., & Altamura, A. C. (2017) · CNS Spectrums · doi:10.1017/s1092852917000773 · Cited by 21
“The selective serotonin reuptake inhibitors (SSRIs) together with the selective serotonin and noradrenaline reuptake inhibitors (SNRIs) represent the mainstay of the pharmacological interventions, with comparable efficacy but greater tolerability compared to tricyclic antidepressants and monoamine oxidase inhibitors (…”
BackgroundAn Analysis of the Slowdown in Growth of Spending for Psychiatric Drugs, 1986–2008
Mark, T. L., Kassed, C. A., Levit, K. R., & Vandivort-Warren, R. (2012) · Psychiatric Services · doi:10.1176/appi.ps.201100564 · Cited by 19
Sakurai, H., Carpenter, L. L., Tyrka, A. R., Price, L. H., Papakostas, G. I., Dording, C. M., Yeung, A., Cusin, C., Ludington, E. A., Bernard-Negron, R., et al. (2019) · Journal of Affective Disorders · doi:10.1016/j.jad.2019.10.040 · Cited by 25
“Thus, the tolerability issue and limited novelty of current pharmacotherapy for depression represent a significant need for exploring new and safer treatments with good tolerability (Chang and Fava, 2010).”
BackgroundProtective effects of VMY-2-95 on corticosterone-induced injuries in mice and cellular models
Yu, Z., Kong, D., Liang, Y., Zhao, X., & Du, G. (2021) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2021.03.002 · Cited by 16
When is antidepressant polypharmacy appropriate in the treatment of depression?
(2014) · Europe PMC (PubMed Central) · doi:10.11919/j.issn.1002-0829.214152 · Cited by 15
“This latter course is the traditional ‘multimodal treatment’,([11]) combining compounds with two independent pharmacological mechanisms that complement each other in terms of treatment effect and tolerance.”
BackgroundИванов, С. В., & Samushiya, M. A. (2014) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s58994 · Cited by 14
“Relatively slow onset of efficacy has been identified as an important limitation of most current antidepressant drugs.(24,25) Perceived improvement early in treatment may be important in maintaining patient confidence in the prescribed treatment, leading to greater adherence and persistence with treatment and improved…”
Seo, R. J., MacPherson, H., & Young, A. H. (2010) · Pharmaceuticals · doi:10.3390/ph3123522 · Cited by 10
“In particular, serotonin reuptake inhibitors (SSRIs) are believed to have good tolerability profiles and accounted for more than half of all antidepressant prescriptions in 2006 [7,8].”
BackgroundBieńkowski, P., Dudek, D., & Samochowiec, J. (2015) · Psychiatria Polska · doi:10.12740/pp/38250 · Cited by 8
“The course of bipolar disorder is highly variable with many patients suffering from multiple episodes of mania and depression leading to social incapacity in about 30% of individuals [12, 24].”
BackgroundMultimodal serotonergic antidepressants
Danilov, D. S. (2017) · S S Korsakov Journal of Neurology and Psychiatry · doi:10.17116/jnevro201711791103-111 · Cited by 6
The Inflammatory Hypothesis of Depression
Soskin, D. P., Cassiello-Robbins, C. F., Isacoff, O. K., & Fava, M. (2012) · FOCUS The Journal of Lifelong Learning in Psychiatry · doi:10.1176/appi.focus.10.4.413 · Cited by 5
Hu, S., Chen, K., Xu, Q., Wang, F., & Na, W.-Q. (2024) · General Hospital Psychiatry · doi:10.1016/j.genhosppsych.2024.09.001 · Cited by 3
Polypharmacy in Psychiatry Practice, Volume II: Use of Polypharmacy in the "Real World"
Ritsner, M. S. (2013) · Springer eBooks · doi:10.1007/978-94-007-5799-8 · Cited by 5
Wojtera, M., & Sobów, T. (2018) · Psychiatria i Psychologia Kliniczna · doi:10.15557/pipk.2018.0010 · Cited by 2
Zhou, Y., Wang, M., Yan, S., Kong, J., & Xie, P. (2021) · Pharmacognosy Magazine · doi:10.4103/pm.pm_85_20 · Cited by 3
Antidepressants in Schizophrenia: A Place for Them?
Terevnikov, V., & Joffe, G. (2012) · Springer eBooks · doi:10.1007/978-94-007-5805-6_9 · Cited by 1
Ketamine in treatment-resistant depression: A review of completed investigations
Verma, S. (2015) · Journal of Mahatma Gandhi Institute of Medical Sciences · doi:10.4103/0971-9903.151741 · Cited by 1
Is There Evidence for the Bipolar Spectrum and the Safety of Pharmaceutical Interventions?
Littrell, J. L. (2012) · Social Work in Mental Health · doi:10.1080/15332985.2011.639928 · Cited by 1
Antidepressant-Antianxiety Agents
Baldessarini, R. J. (2012) · Springer eBooks · doi:10.1007/978-1-4614-3710-9_4 · Cited by 1
Major depressive disorder: treatment and future perspective
Gersner, R., Rosenberg, O., & Dannon, P. N. (2012) · Clinical Practice · doi:10.2217/cpr.12.23 · Cited by 1
Hell, D. (2015) · Forum Médical Suisse ‒ Swiss Medical Forum · doi:10.4414/fms.2015.02269
MATERNAL DEPRESSIVE SYMPTOMS AND HEALTH OUTCOMES IN YOUTHS WITH TYPE 1 DIABETES: A MEDIATIONAL MODEL
Morgan, S. K. (2010) · VCU Scholars Compass (Virginia Commonwealth University) · doi:10.25772/f3s8-4095 · Cited by 1
Macaluso, M. (2026) · Journal of Psychiatric Practice · doi:10.1097/pra.0000000000000947
Metadata
- Authors
- Chang, T., & Fava, M.
- Affiliations
- Massachusetts General Hospital (US)
- ORCID
- Chang, Trina
- Venue
- The Journal of Clinical Psychiatry
- Publisher
- Physicians Postgraduate Press, Inc
- Published
- 2010-08-15
- Volume
- 71
- Issue
- 08
- Pages
- 971-975
- ISSN
- 0160-6689 (ISSN-L)
- OpenAlex
- W2034147634
- Semantic Scholar
- d6d3f91d58f90222f3bf16c9a0e933fdb631ec3e
- Cited by
- 50
- References
- 0
- Citations by year
- 2026: 1 · 2024: 1 · 2023: 1 · 2021: 2 · 2020: 1 · 2019: 5 · 2018: 2 · 2017: 3 · 2016: 2 · 2015: 7 · 2014: 3 · 2013: 2 · 2012: 9
- FWCI
- 5.43
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Clinical Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute of Mental Health (T32MH19126, T32MH019126)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Keywords
- depression, antidepressants, major depressive disorder, neurokinin receptor antagonists, nicotinic agonists, antidepressant tolerability, sexual dysfunction, weight gain, cognitive impairment
- MeSH terms
- Antidepressive Agents, Depressive Disorder, Major, Major Depressive Disorder, Depressive Disorder, Europe, Humans, Psychopharmacology, United States, Treatment Outcome, Drug Approval, Drug Discovery
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.